Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma

• Ngā kaituhi matua: Xiaohua Gong (Author), Ayman Akil (Author), Andre Ndi (Author), Tao Ji (Author), Xiang Liu (Author), Mark Lovern (Author), Xuejun Chen (Author)
• Hōputu: Pukapuka
• I whakaputaina: Wiley, 2023-11-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Abstract Pemigatinib is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR)1-3 with efficacy in patients with previously treated, advanced/metastatic cholangiocarcinoma (CCA) with FGFR2 alterations. A previously developed population pharmacokinetic (PK) model of pemigatin...